Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nanobiotix (NBTX) Non-Current Debt (2018 - 2025)

Nanobiotix has reported Non-Current Debt over the past 8 years, most recently at $105.9 million for Q4 2025.

  • For Q4 2025, Non-Current Debt rose 115.62% year-over-year to $105.9 million; the TTM value through Dec 2025 reached $105.9 million, up 115.62%, while the annual FY2025 figure was $105.9 million, 115.62% up from the prior year.
  • Non-Current Debt for Q4 2025 was $105.9 million at Nanobiotix, up from $52.6 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $105.9 million in Q4 2025 and troughed at $28.1 million in Q4 2022.
  • A 5-year average of $51.5 million and a median of $48.5 million in 2023 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: crashed 35.14% in 2022 and later soared 115.62% in 2025.
  • Year by year, Non-Current Debt stood at $43.3 million in 2021, then crashed by 35.14% to $28.1 million in 2022, then skyrocketed by 74.65% to $49.0 million in 2023, then increased by 0.27% to $49.1 million in 2024, then soared by 115.62% to $105.9 million in 2025.
  • Business Quant data shows Non-Current Debt for NBTX at $105.9 million in Q4 2025, $52.6 million in Q2 2025, and $49.1 million in Q4 2024.